Syngenis banks $4M pre-float to power AI-driven biotech platform
Perth-based Syngenis Labs raised $4 million in an oversubscribed pre-float to enhance its AI-driven biotech platform. The funding aims to expedite the development of RNA and DNA-based medicines while building a GMP facility set to be operational by January 2024. Syngenis seeks to capture value in Australia’s growing genetic medicine sector by controlling the entire development process.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 13 Jul 2026, 00:46 UTC · Updated 13 Jul 2026, 00:50 UTC
Summary by OZbrief Editorial. Original report: SMH. Editorial policy · Corrections
Trending
- BYD refunds 1,265 customers after selling incorrect 2025 car models
- Telstra network outage prompts Senate hearing after avoidable server failure
- Jeremy Cameron hospitalized with suspected broken collarbone after Geelong's loss
- Transport officials stumble on north shore road changes ‘on developer’s website’
- Grandmother's 32-hour bus 'adventure' home after train shutdown
- AFLW star Zarlie Goldsworthy goes viral with TikTok reaction video